Switch theme
Sign up to access all valuation multiples
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
2011
14
Last FY Revenue n/a
LTM EBITDA -$26.8M
$6.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CalciMedica has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$26.8M.
In the most recent fiscal year, CalciMedica achieved revenue of n/a and an EBITDA of -$24.1M.
CalciMedica expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CalciMedica valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$26.8M | XXX | -$24.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$25.7M | XXX | -$24.2M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$18.0M | XXX | -$13.7M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 4, 2025, CalciMedica's stock price is $2.
CalciMedica has current market cap of $22.5M, and EV of $6.5M.
See CalciMedica trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.5M | $22.5M | XXX | XXX | XXX | XXX | $-1.38 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 4, 2025, CalciMedica has market cap of $22.5M and EV of $6.5M.
CalciMedica's trades at n/a EV/Revenue multiple, and -0.3x EV/EBITDA.
Equity research analysts estimate CalciMedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CalciMedica has a P/E ratio of -1.2x.
See valuation multiples for CalciMedica and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $22.5M | XXX | $22.5M | XXX | XXX | XXX |
| EV (current) | $6.5M | XXX | $6.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.2x | XXX | -0.3x | XXX | XXX | XXX |
| EV/EBIT | -0.3x | XXX | -0.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.2x | XXX | -1.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCalciMedica's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.7M for the same period.
CalciMedica's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CalciMedica's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CalciMedica and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CalciMedica acquired XXX companies to date.
Last acquisition by CalciMedica was XXXXXXXX, XXXXX XXXXX XXXXXX . CalciMedica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CalciMedica founded? | CalciMedica was founded in 2011. |
| Where is CalciMedica headquartered? | CalciMedica is headquartered in United States of America. |
| How many employees does CalciMedica have? | As of today, CalciMedica has 14 employees. |
| Who is the CEO of CalciMedica? | CalciMedica's CEO is Dr. A. Rachel Leheny, PhD. |
| Is CalciMedica publicy listed? | Yes, CalciMedica is a public company listed on NAS. |
| What is the stock symbol of CalciMedica? | CalciMedica trades under CALC ticker. |
| When did CalciMedica go public? | CalciMedica went public in 2020. |
| Who are competitors of CalciMedica? | Similar companies to CalciMedica include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of CalciMedica? | CalciMedica's current market cap is $22.5M |
| Is CalciMedica profitable? | Yes, CalciMedica is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CalciMedica? | CalciMedica's last 12 months EBITDA is -$26.8M. |
| What is the current EV/EBITDA multiple of CalciMedica? | Current EBITDA multiple of CalciMedica is -0.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
